Demand for effective treatments is rising as cancer incidence rates rise. Worldwide, there are more people being diagnosed with various malignancies, including lung, blood, breast, and liver cancers. According to the International Agency for Research on Cancer's (IARC) GLOBOCAN 2020 projections of cancer incidence and mortality, there were approximately 10 million cancer deaths and 19.3 million new cancer cases worldwide in 2020. The National Cancer Institute estimates that in the US in 2018, there were 609,640 cancer-related deaths and 1,735,350 new cases of the disease.
The key causes of the rising incidence of cancer around the world include excessive smoking, alcohol drinking, and cigarette use that helps in growing demand of Tumor Ablation Market. Patient enrollment in the critical U.S. trial, which aimed to demonstrate the security and effectiveness of TechsoMed's flagship product, BioTraceIO, in providing practical visualisation and quantitative insights on procedure results in liver cancer patients undergoing ultrasound-guided percutaneous ablation procedures, has successfully been completed, the company announced today. The first-of-its-kind AI algorithm-driven tissue viability imaging tool was developed by TechsoMed.
Read More- https://cmi-latestreportorientedblogs.blogspot.com/2022/12/tumor-ablation-market-to-surpass-us.html
